The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 4 briefings matching “diabetes”

Reset all filters

Gastroenterology

Gastroenterology Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

GASTROENTEROLOGY · REAL-WORLD COHORT

Prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the CHESS-LiverHealth project): cross-sectional baseline data from a prospective cohort study

Silent Liver Damage: A Hidden Epidemic in China's Adult Population. Liver scarring and fatty liver disease are widespread among Chinese adults, largely fueled by metabolic issues and alcohol.

4/5 Strong Trial

Evidence Meter · 4/5

Strong Clinical Evidence

Tested directly in patients through a prospective clinical trial or large multicenter human cohort.

1 min readThe Lancet Gastroenterology & HepatologyNov 15, 2026

GASTROENTEROLOGY · PHASE III

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study

In patients with MASH, 48 weeks of pemvidutide treatment led to significant reductions in non-invasive tests of MASH inflammation and fibrosis (tissue scarring), suggesting continued improvement in liver health. These data warrant the continued investigation of pemvidutide in a Phase 3 trial.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Gastroenterology & HepatologyNov 11, 2026

GASTROENTEROLOGY · REAL-WORLD COHORT

Steatotic Liver Disease Is Becoming a Higher Priority Worldwide

This Medical News article discusses international efforts to determine the prevalence and increase awareness and detection of steatotic liver disease, which affects an estimated 1.7 billion people worldwide, including most individuals with obesity or type 2 diabetes. Published in JAMA, these peer-reviewed gastroenterology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readJAMAOct 23, 2026

GASTROENTEROLOGY · CLINICAL PRACTICE

Obesity in Children Aged 2 to 12 Years: A Review

Obesity in children is associated with chronic disease, such as hypertension, and with poor quality of life. Evidence-based treatment for obesity in children includes intensive health behavior and lifestyle treatment, and pharmacotherapy may provide additional benefit, although short- and long-term safety and efficacy (real-world effectiveness in the trial) data are limited.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readJAMAOct 21, 2026

Interactive Fact Check